David B. Sacks, MD, MB, ChB, FRCPath, FACB
David B. Sacks, MD, MB, ChB, FRCPath, FACB, is associate professor of pathology at Harvard Medical School and medical director of clinical chemistry at Brigham and Women’s Hospital in Boston.
His scientific work is in the area of intracellular signal transduction, with a focus on calcium and calmodulin signaling. Initially, Dr. Sacks investigated the role of calmodulin in insulin action. Working with Jay McDonald, Jack Ladenson, and Sharon Porter at Washington University, he developed the first monoclonal antibody to calmodulin. The remarkable conservation of amino acid sequence of calmodulin among organisms had prevented prior antibody development. Subsequently, his research focused on nonclassic calmodulin targets and the functional sequelae of the interactions of calmodulin with these divergent proteins.
He is currently pursuing the possible role of calmodulin and its interactions with selected binding proteins in neoplastic transformation and metastasis. His primary clinical focus is on diabetes mellitus, with an emphasis on the interface between the clinical laboratory and patient care.
He works closely with the American Diabetes Association and is actively engaged in enhancing the quality of laboratory testing in patients with diabetes, serving as Chair of the National Glycohemoglobin Standardization Program (NGSP) steering committee. In addition, he serves on several other diabetes committees, including the International Federation for Clinical Chemistry (IFCC) Working Group on HbA1c Standardization.
Dr. Sacks has lectured extensively and has published numerous papers in peer-reviewed journals. He has served on the editorial board of Clinical Chemistry since 1995 and is currently an associate editor. He also serves on the editorial boards of the Journal of Biological Chemistry, American Journal of Pathology, Clinical Proteomics, Clinical Biochemist Reviews, American Journal of Clinical Pathology, and Biochemical Journal.